1,095 results on '"Dreicer, Robert"'
Search Results
302. Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
303. Interdisciplinary Management of Locally Advanced and Metastatic Genitourinary Cancers: A Team Sport
304. Challenges with genomic testing in pancreaticobiliary cancers: Results of a prospective cohort study.
305. Genomic testing to enhance treatment choices and clinical trial accrual in metastatic colorectal cancer: Results of a prospective cohort study.
306. Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
307. Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum
308. A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T
309. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
310. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
311. PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
312. First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.
313. Therapeutic Advances in Prostate Cancer.
314. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
315. The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.
316. Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.
317. A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN).
318. Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients.
319. A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
320. Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial.
321. Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)
322. MP70-20 A PHASE 2 TRIAL OF PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN TAXANE-TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
323. Computed Tomography Characteristics of Unresectable Primary Renal Cell Carcinoma Treated With Neoadjuvant Sunitinib
324. Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
325. Risk for Developing Myelodysplastic Syndromes in Prostate Cancer Patients Definitively Treated With Radiation
326. A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
327. Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).
328. Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233.
329. Editorial Comment
330. Clinical activity of abiraterone acetate in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
331. Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
332. Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): Results from a phase II study of OSI-906 (linsitinib).
333. A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
334. Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma.
335. The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
336. A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
337. Immune cell repertoire in patients with indolent metastatic renal cell carcinoma.
338. A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
339. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant Settings
340. Defining Clinical Endpoints in Castration-Resistant Prostate Cancer.
341. Differential Immunologic and MicroRNA Effects of 2 Dosing Regimens of Recombinant Human Granulocyte/Macrophage Colony Stimulating Factor
342. Phase I trial of pomalidomide given for patients with advanced solid tumors
343. Targeting mTOR and VEGF in CRPC: Preliminary results of a phase I/II trial of temsirolimus (T) and bevacizumab (B) in docetaxel-refractory metastatic CRPC.
344. A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy.
345. Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC).
346. The association between the treatment-induced hypertension (Htn) and response to neoadjuvant sunitinib in renal cell carcinoma (RCC).
347. Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
348. A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
349. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
350. The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.